Anti-stathmin gene therapy - Gradalis

Drug Profile

Anti-stathmin gene therapy - Gradalis

Alternative Names: pbi-shRNA STMN1 LP; pbi-shSTMN1 LP

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gradalis
  • Developer Gradalis; Mary Crowley Cancer Research Center
  • Class Gene therapies
  • Mechanism of Action Stathmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (Intratumoural, Injection)
  • 13 Apr 2017 Strike Bio completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT01505153)
  • 29 Feb 2012 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT01505153)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top